COMMUNIQUÉS West-GlobeNewswire

InflaRx Announces Participation in February Investor Conferences
29/01/2026
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
29/01/2026
CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
29/01/2026
Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage [...]
Immutep Quarterly Activities Report Q2 FY26
29/01/2026
Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January 2026, Immutep [...]
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
29/01/2026
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first [...]
Soleno Therapeutics to Participate in Upcoming Conferences
29/01/2026
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
29/01/2026
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Beghou’s Biopharma Commercialization Research Report Reveals Top Challenges, Opportunities, and Investment for Life Sciences Industry in 2026
29/01/2026
New research shows teams are struggling to execute coordinated actions across data, access, and omnichannel, leading to persistent gaps in performance AI is a top priority, but many technologies remain uneven in [...]
InnovAge Expands Board with Appointment of Two Directors
29/01/2026
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
29/01/2026
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH-1, NCT03073967 ) [...]
Dogecoin Cash, Inc. Announces Completion of Unit Distribution Processing and DTC Participant Allocation
29/01/2026
MESQUITE, NV, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Mesquite, Nevada - January 29, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) (the "Company") today announced that Colonial Stock Transfer Company, Inc. ("Colonial"), the Company' [...]
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
29/01/2026
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
29/01/2026
BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
29/01/2026
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a capital-efficient [...]
Communiqué de presse : 2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026
29/01/2026
2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026. Paris, le 29 janvier 2026 Ventes du T4 en progression de 13,3 % à TCC 1 et BNPA 2 des activités de [...]
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
29/01/2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab Développement basé sur un fort rationnel biologique de l’IL-7R La pouchite chronique [...]
Interim Results for the six months ended 31 October 2025
29/01/2026
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a business update and [...]

Pages